Stargardt Disease Epidemiology Forecast - 2036

Published Date : 2026
Pages : 66
Region :

Stargardt Disease Epidemiology Summary

  • Stargardt disease is the most common inherited macular dystrophy in children and young adults, primarily caused by ABCA4 mutations that lead to toxic lipofuscin accumulation in the retina, progressive photoreceptor degeneration, and central vision loss.
  • The diagnostic prevalence in the United States is likely lower due to a non-centralized healthcare system, lack of specific diagnostic codes, and disparities in access to healthcare.
  • Stargardt disease is a rare inherited retinal disorder, with prevalence generally estimated at approximately 1 in 8,000–10,000 individuals, although rates vary across geographic regions and populations.
  • Within the EU4 and the UK, Germany is estimated to account for the highest number of diagnosed prevalent cases, followed by France, while Spain represents the smallest patient population, broadly reflecting differences in population size and diagnosis rates.
  • The prevalence of Stargardt disease appears to be lower in certain Asian populations, including Japan, compared with North American and European populations, reflecting potential differences in genetic background and disease ascertainment.
  • Males and females are affected at broadly comparable rates, consistent with the predominantly autosomal-recessive inheritance pattern of Stargardt disease.
  • The epidemiological profile is largely driven by biallelic ABCA4 variants, with differences in variant frequencies across populations contributing to geographic variation in disease prevalence.

 

Stargardt Disease Epidemiology Forecast in the 7MM

  • 2025 Diagnosed Prevalent Cases of Stargardt Disease: ~XXX
  • 2036 Projected Diagnosed Prevalent Cases of Stargardt Disease: ~XXX
  • Stargardt Disease Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Stargardt Disease – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the stargardt disease, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period

2022–2036

Historical Year

2022–2025

Forecast Period

2026–2036

Base Year

2026

Geographies Covered

  • North America : The US;
  • Europe: Germany, France, Italy, and Spain and the UK;
  • Asia-Pacific: Japan;

Stargardt Disease Epidemiology CAGR

(Forecast period)

~XX% (2026–2036)

Stargardt Disease Epidemiology Segmentation Analysis

Patient Burden Assessment

  • Stargardt disease Total Diagnosed Prevalent Cases
  • Stargardt disease Type-specific Diagnosed Prevalent Cases
  • Stargardt disease Symptom-specific Diagnosed Prevalent Cases
  • Stargardt disease Total Treated Cases

Stargardt Disease Understanding and Diagnosis Algorithm

Stargardt Disease Overview and Diagnosis

Stargardt disease is a rare inherited retinal disorder, most commonly caused by ABCA4 mutations and typically inherited in an autosomal recessive manner. It is characterized by lipofuscin accumulation in the retinal pigment epithelium, leading to progressive photoreceptor and RPE degeneration. Patients commonly develop central vision loss, reduced visual acuity, color vision impairment, and central scotomas during childhood or adolescence. Although no disease-modifying therapy is currently approved, advances in gene therapy, visual cycle modulation, optogenetics, and RNA-based approaches are expanding therapeutic opportunities.

Further details are provided in the report.

Stargardt Disease Diagnosis

Stargardt disease is a rare inherited retinal disorder, most commonly caused by ABCA4 mutations, resulting in progressive macular and retinal pigment epithelium degeneration and central vision loss. Diagnosis combines clinical examination, visual function assessment, multimodal retinal imaging such as OCT and fundus autofluorescence, and molecular genetic testing to confirm pathogenic variants and support patient stratification. Currently, treatment is primarily supportive, including low-vision rehabilitation and regular ophthalmic monitoring, while gene therapies, visual-cycle modulators, and other disease-modifying approaches are being investigated.

Further details are provided in the report.

Stargardt Disease Epidemiology

Key Findings from Stargardt Disease Epidemiological Analysis and Forecast 

  • The diagnostic prevalence in the United States is likely lower due to a non-centralized healthcare system, lack of specific diagnostic codes, and disparities in access to healthcare.
  • According to the research by Foundation Stargardt the global prevalence of ABCA4 gene mutation is around 1.2 per 10,000, which accounts for approximately 40,000 prevalent cases in the North America.
  • Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of Stargardt disease in 2025, followed by France, while Spain represented the smallest patient population.
  • As per the analysis, in the United States, the 10–20 years age group accounted for the highest number of diagnosed prevalent cases in 2025, reflecting the typical onset of Stargardt disease during childhood and adolescence.
  • According to analysis, ABCA4-associated Stargardt disease represented the overwhelming majority of diagnosed cases in 2025, while Stargardt-like phenotypes associated with ELOVL4, PROM1, and other rare genetic variants accounted for only a small proportion of the overall patient population.
  • The estimated prevalence of Stargardt Disease is 1 in 8,000–10,000 individulas in North America. Moreover, the data from the study indicated towards a lower prevalence of Stargardt Disease in Japanese  inherited retinal dystrophies populations.
  • Before the Stargardt Disease gene was discovered, a widely circulated estimate of 1 in 10,000 was published in the 1980s based on empirical data. Although the estimated diagnosed prevalence of Stargardt Disease in the 7MM could fall between 1 in 15,000–20,000, it is based on data from countries with centralized healthcare systems, suggesting that the true frequency may be greater.

Scope of the Report

  • The report covers a segment of a descriptive overview of Stargardt disease, explaining their causes, signs and symptoms, and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Stargardt Disease Patient Population Forecast

Report Key Strengths

  • Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
  • 11-year Forecast
  • Patient Burden Trends (by geography)

FAQs

  • What are the disease risks, burdens, and unmet needs of Stargardt disease? What will be the growth opportunities across the 7MM concerning the patient population with Stargardt disease?
  • What is the historical and forecasted Stargardt disease patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Tags:

  • Stargardt Disease (STGD)
  • Stargardt Disease (STGD) Epidemiology
  • Stargardt Disease (STGD) Market
  • Stargardt Disease (STGD) Pipeline

Related Reports

report image delveinsight

Stargardt Disease Pipeline Insight, 2026

report image delveinsight

Stargardt Disease Market Insight, Epidemiology And Market Forecast - 2036

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports